New GLP-1 Drugs: Pills, Pipeline Shots and What Comes Next
The next GLP-1 medicines are in late trials: retatrutide, CagriSema, amycretin and others. Each row shows who makes it, how it works, the stage it has reached and the best trial result published.
- Molecules tracked
- 13
- Sources
- ClinicalTrials.gov, manufacturers' results
| Molecule | Manufacturer | How it works | Form | Stage | Best trial weight loss | Next step |
|---|---|---|---|---|---|---|
| CagriSema (cagrilintide plus semaglutide) | Novo Nordisk | A weekly shot that pairs semaglutide with cagrilintide, an amylin analogue. | weekly injection | filed with FDA | 20.4% | FDA review in 2026 |
| Retatrutide | Eli Lilly | One weekly shot works on three hormone receptors, which include GIP, GLP-1 and glucagon. | weekly injection | Phase 3 (completed key trials) | 22.6% | BLA submission Q1 2027 |
| Survodutide | Boehringer Ingelheim | A weekly shot that works as a dual agonist on both glucagon and GLP-1 receptors. | weekly injection | Phase 3 (results reported 2026) | 16.6% | Not listed |
| MariTide (maridebart cafraglutide) | Amgen | Given monthly, this antibody-peptide shot blocks GIP receptors and turns on GLP-1 receptors. | monthly injection | Phase 3 (MARITIME program) | 16.2% | Phase 3 MARITIME underway |
| Amycretin | Novo Nordisk | One molecule targets GLP-1 and amylin receptors. Researchers have studied it as a weekly injection and as a daily pill. | weekly injection or daily pill | Phase 3 | 24.3% | advancing to Phase 3 (shot and pill) |
| Eloralintide | Eli Lilly | A weekly injection that selectively activates amylin receptors; trials have also paired it with tirzepatide (EloraTZP). | weekly injection | Phase 3 | 20.1% | Phase 3 enrolling from Dec 2025 |
| Bimagrumab | Eli Lilly | This antibody was tested with semaglutide. It blocks activin type II receptors and aims to reduce fat while keeping muscle. | IV infusion every 12 weeks (in trial) | Phase 2 | Not listed | Not listed |
| Mazdutide | Innovent Biologics (licensed from Eli Lilly) | A weekly shot that works as a dual agonist on both glucagon and GLP-1 receptors. | weekly injection | approved in China | Not listed | Not listed |
| VK2735 | Viking Therapeutics | This dual agonist acts on GLP-1 and GIP. It has been tested as a weekly shot and as a daily pill. | weekly injection or daily pill | Phase 3 | 14.7% | SUNRISE Phase 3 started Oct 2026 |
| Pemvidutide | Altimmune | This weekly injection was developed mainly for fatty liver disease (MASH). It has balanced glucagon and GLP-1 activity. | weekly injection | Phase 3 (MASH) | Not listed | PERFORMA Phase 3 started Aug 2026 |
| Petrelintide | Zealand Pharma with Roche | Given as a weekly shot, this long-acting amylin analog offers another option to GLP-1 drugs. | weekly injection | Phase 2 (completed) | 10.7% | Not listed |
| Metsera drugs (MET-097i, MET-233i), now Pfizer | Pfizer (acquired Metsera) | MET-097i is a GLP-1 shot you take weekly or monthly; MET-233i, in contrast, is a monthly amylin analog. | weekly or monthly injection | Phase 3 starting (MET-097i) | 12.3% | 10 Phase 3 trials in 2026 |
| Orforglipron (Foundayo) | Eli Lilly | A daily GLP-1 pill (small molecule) with no food or water rules. | daily pill | approved | 12.4% | Not listed |
Download the pipeline table as CSV
Sources (13)
prnewswire.com 1 2 3 4, boehringer-ingelheim.com, NEJM, investors.amgen.com, ir.vikingtherapeutics.com 1 2, altimmune.com, roche.com, pfizer.com, Eli Lilly.
Weight loss and half-life, at a glance
Half-life in days: how long the body needs to clear half of a dose. These figures come from section 12.3 in each FDA label.
Percentage of body weight. Trials, doses and lengths differ, so compare each one with its own placebo on its page.